Drugs / TY101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04458389 | Dec 2020 → Jun 2024 | lymphoma | Tayu Huaxia Biotech Medical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TY101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04458389 ↗ |
| Modality | Monoclonal antibody | “Humanized anti-PD-1 monoclonal antibody” NCT04458389 ↗ |
| Route | Intravenous | “injected intravenously” NCT04458389 ↗ |